PDS01ADC Shows 78% ORR, >80% 2-Year Survival in mCRC Phase 2 Trial, Data Published
PDSB has more than doubled off its 52-week low of $0.507.
Summary
PDS Biotech announced the publication of positive interim Phase 2 clinical trial data for its PDS01ADC in metastatic colorectal cancer (mCRC). Data from Stage 1 (N=9) of an NCI-led trial showed a 78% objective response rate (ORR) and an approximate 85% 2-year survival rate. These results compare favorably to a parallel trial without PDS01ADC, which had a 35% ORR and ~40% 2-year survival rate. This is highly significant as the trial targets unresectable MSS or pMMR mCRC, a patient population where immune checkpoint inhibitors have been largely ineffective. For a small-cap immunotherapy company, these strong efficacy signals, published in a reputable journal, represent a material de-risking event and could lead to substantial investor interest and stock price movement. Investors will now watch for further trial progression, including Stage 2 data, and potential strategic developments.
At the time of this announcement, PDSB was trading at $1.08 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $59.2M. The 52-week trading range was $0.51 to $1.92. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.